In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 35-42

  Dembry, L M ^a,b   Farrel, P A ^a   Orcutt, D R ^a   Gerrity, L A ^a   Andriole, V T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GENTAMICIN; OFLOXACIN; SULTAMICILLIN; TROVAFLOXACIN; VANCOMYCIN;

AEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CITROBACTER FREUNDII; CONTROLLED STUDY; DILUTION; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PROTEUS MIRABILIS; PROTEUS VULGARIS; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0030757121     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.35     Document Type: Article

References (13)

1. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J., & Moellering R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
2. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
3. Gootz, T. D., Brighty, K. E., Anderson, M. R., Schmieder, B. J., Haskell, S. L, Sutcliffe, J. A. et al. (1994). In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 19, 235-43.
4. Brown, D. F. & Brown, L. (1991). Evaluation of the E test, a novel method of quantifying antimicrobial activity. Journal of Antimicrobial Chemotherapy 27, 185-90.
5. Miller, L. A., Rittenhouse, S. F., Utrup, L. J. & Poupard, J. A. (1994). Comparison of three methods for determination of a single MIC of an antimicrobial agent. Journal of Clinical Microbiology 32, 1373-5.
6. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA.
7. Sabath, L. D., McCall, C. E., Steigbigel, N. H. & Finland, M. (1967). Synergistic penicillin combinations for treatment of human urinary-tract infections. Antimicrobial Agents and Chemotherapy 6, 149-55.
8. King, T. C., Schlessinger, D. & Krogstad, D. J. (1981). The assessment of antimicrobial combinations. Reviews of Infectious Diseases 3, 627-33.
9. Andriole, V. T. (1971). Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas. Journal of Infectious Diseases124, Suppl., S46-S55.
10. Neu, H. C. & Chin, N. X. (1994), In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
11. 11. Baker, C. N., Stocker, S. A., Culver, D. H. & Thornsberry, C. ' (1991). Comparison of the E test to agar dilution, broth microdilu5 tion, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. Journal of Clinical Microbiology 29, 533-8.
12. Hamilton-Miller, J. M. T., Shah, S. & Yam, T. S. (1995). Errors arising from incorrect orientation of E test strips. Journal of Clinical Microbiology 33, 1966-7.
13. Eliopoulos, G. M. & Eliopoulos, C. T. (1989). Ciproftoxacin in combination with other antimicrobials. American Journal of Medicine 87, Suppl. 5A, 17S-22S.